Denali Therapeutics Inc.

Glaxo Group Limited

Chronos Therapeutics Limited

Colin Philip Leslie

Zachary Kevin Sweeney

Anthony A Estrada

Javier De Vicente Fidalgo

Jianwen A Feng

Brian M Fox

Joseph P Lyssikatos

Maksim Osipov

Cheng Hu

Alfonso Pozzan

Jessica Tibasco

Cinzia Maria Francini

Alessandro Falchi

Anantha R Sudhakar

Giorgio Bonanomi

Domenica Antonia Pizzi

Matteo Biagetti

Giancarlo Merlo

Marilisa Rinaldi

Luigi Piero Stasi

Simon Edward Ward

Barbara Bertani

Markus Bergauer

Arun Thottumkara

Christopher R H Hale

Elena Serra

Steven Mark Bromidge

Antonio Kuok Keong Vong

Fabrizio Micheli

Luca Tarsi

Susanna Cremonesi

Teresa Semeraro

Carmela Napolitano

Tim Luker

Federica Tonelli

The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

Kinase inhibitors and uses thereof

The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.

Compounds, compositions and methods

Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)

The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R, R, R, R, R, R, R, R, R, R, m, n, A, L and B are as defined herein. 

N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system

Disclosed are methods for the preparation of compounds of formula (I): wherein R, m, X, R, n, W, p, Y, Z, R, R, Rand q have the meanings as defined in the description.

Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors

Disclosed are methods for use of compounds of formula (I) in combination with other active substances in the treatment of CNS disorders such as depression or anxiety. wherein R, m, X, R, n, W, p, Y, Z, R, R, Rand q have the meanings as defined in the description.

Compounds of formula (I) and pharmaceutically acceptable salts thereof are provided: wherein R, m, X, R, n, W, p, Y, Z, R, R, Rand q have the meanings as defined in the description. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression or anxiety, are also disclosed.

Growing community of inventors

Verona, Italy

Colin Philip Leslie